Browse August's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.
Adding pembrolizumab to chemotherapy significantly improves the overall survival of people with advanced triple-negative breast cancer and a tumoral PD-L1 combined positive score of at least 10, demonstrate phase 3 trial data.
The addition of nivolumab to neoadjuvant chemotherapy significantly improves the progression-free survival and overall survival of individuals with resectable stage IIIA–B non-small-cell lung cancer, suggest data from NADIM II.
Combination therapy with pembrolizumab plus axitinib results in similar health-related quality of life outcomes to that with sunitinib monotherapy for untreated advanced renal cell carcinoma, KEYNOTE-426 study data show.